NL-OMON50643已完成2 期
Treating microalbuminuria over 24 weeks in subjects with or without type 2 diabetes or hypertension - TIMOTHY
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 340
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age 45 to 80 years
- •Persistent urinary albumin:creatinine ratio (UACR) >= 2.5 mg/mmol (~25 mg/g)
- •Willing to sign informed consent
排除标准
- •Diagnosis of type 1 diabetes mellitus
- •eGFR < 25 ml/min/1.73m2
- •UACR > 3500 mg/g
- •Concurrent treatment with SGLT2 inhibitor
- •Receiving immunosuppressive therapy within 6 months prior to enrollment
- •History of diabetic ketoacidosis
- •Active malignancy aside from treated squamous cell or basal cell carcinoma
- •of the skin.
- •Initiation or changes in the dose of interventions in the
- •renin-angiotensin-aldosterone-system, diuretics, GLP-1 receptor agonists within
- •6 weeks of screening will not be allowed.
- •Any medication, surgical or medical condition which might significantly alter
- •the absorption, distribution, metabolism, or excretion of medications
- •including, but not limited to any of the following:
- •o History of active inflammatory bowel disease within the last six months;
- •o Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy,
- •or bowel resection;
- •o Gastro-intestinal ulcers and/or gastrointestinal or rectal bleeding within
- •last six months;
- •o Pancreatic injury or pancreatitis within the last six months;
- •o Evidence of hepatic disease as determined by any one of the following: ALT or
- •AST values exceeding 3x ULN at the screening visit, a history of hepatic
- •encephalopathy, a history of esophageal varices, or a history of portocaval
- •o Evidence of urinary obstruction or difficulty in voiding at screening
- •History of severe hypersensitivity or contraindications to dapagliflozin
- •Subjects who, in the assessment of the investigator, may be at risk for
- •dehydration or volume depletion that may affect the interpretation of efficacy
- •or safety data
- •Participation in any clinical intervention study within 3 months prior to
- •initial dosing.
- •History of drug or alcohol abuse within the 12 months prior to dosing, or
- •evidence of such abuse as indicated by the laboratory assays conducted during
- •the screening.
- •History of noncompliance to medical regimens or unwillingness to comply with
- •the study protocol.
- •Any surgical or medical condition, which in the opinion of the investigator,
- •may place the patient at higher risk from his/her participation in the study,
- •or is likely to prevent the patient from complying with the requirements of the
- •study or completing the study.
- •Pregnancy or breastfeeding
研究者
相似试验
进行中（未招募）
1 期
Treating mild kidney failure over 24 weeks in people with or without type 2 diabetes or high blood pressureMicroalbuminuriaMedDRA version: 20.1Level: PTClassification code 10027525Term: MicroalbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2021-004073-31-NLniversity Medical Center Groningen340
招募中
2 期
ANIfrolumab treatment for 24 weeks in patients with primary Sjögren*s syndrome - Efficacy and safety assessment in a randomized, double-blind, placebo-controlled phase-IIa proof-of-concept trial (ANISE-II)Primary Sjögren's syndrome10003816NL-OMON51816niversitair Medisch Centrum Groningen30
进行中（未招募）
不适用
A Study of Long-term Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic RhinitisPerennial Allergic RhinitisEUCTR2014-004922-16-Outside-EU/EEACorporation Schering-Plough K.K.80
已完成
不适用
Can We Alter Risk Factors For Oesophageal Cancer With Exercise?Barrett's OesophagusOesophageal Adenocarcinoma preventionDiet and Nutrition - ObesityPhysical Medicine / Rehabilitation - PhysiotherapyCancer - Oesophageal (gullet)ACTRN12609000401257Burns, Trauma and Critical Care Research Centre, School of Medicine, University of Queensland120
已完成
2 期
Phase II study of weekly amrubicin in patients with refractory or relapsed non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000002570ational Hospital Organization Nagoya Medical Center43